Most physicians adhere to guideline-directed medical therapies for HFrEF based on the 2021 European Society of Cardiology HF guidelines.

The presence or absence of left ventricular hypertrophy may predict the effect of finerenone on heart failure hospitalization risk in patients with CKD and type 2 diabetes.

The heart is a muscle like no other, beating 60 to 100 times per minute on average, around the clock. But when it grows weak, it can lead to serious problems: from debilitating shortness of breath and ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.